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Objectives: Although mitral valve repair is rarely required in neonates, this population is
considered to be at high risk for adverse outcomes. The aim of this study was to review
the indications for surgery, mechanisms, repair techniques, and mid-term outcomes of
neonatal mitral valve repair.
Methods: The demographic, procedural, and outcome data were obtained for all
neonates who underwent mitral valve repair from 2005 to 2012. The primary endpoints
included mortality, transplantation, and mitral valve reoperation.
Results: Twenty patients were included during the study period. Median age at operation
was 11days (range: 3–25). Eleven patients (55%) presented with mitral stenosis, three
had regurgitation (15%), and six had mixed mitral disease (30%). Nineteen of 20 patients
had mild or less regurgitation on immediate postoperative imaging. During a median
follow-up of 5months (1month–4.8 years), six patients died at a median of 33months
(7–41months) from repair and one patient required orthotopic heart transplantation. Six
patients required mitral valve reoperation, five for mitral valve re-repair, and one for mitral
valve replacement. Freedom from death, transplantation, or mitral valve replacement was
84.28.4% at 1month, 71.311% at 6months, 64.112% at 1 year, and 51.315%
at 2 years and was worse for patients presenting with mitral regurgitation compared to
stenosis or mixed mitral valve disease.
Conclusion: Although mitral valve repair can be performed with acceptable immediate
postoperative result, this procedure carries a high burden of late death and mitral valve
reoperations.
Keywords: mitral valve, mitral valve repair, neonatal, congenital heart disease, surgery
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INTRODUCTION
Repair of mitral valve disease in children has been steadily
increasing (1), and the results following complex reconstruc-
tion are improving (1–8). Congenital mitral valve disease rarely
requires intervention in the neonatal period. When associated
with hypoplasia of other left heart structures as part of borderline
hypoplastic left heart syndrome, it may be managed by single
ventricle palliation. With improving results in the management
of congenital mitral disease in children and consideration for
biventricular repair in borderline hypoplastic left heart syndrome,
either through primary left ventricular rehabilitation (9) or sec-
ondary left ventricular recruitment (10), more patients are being
referred for neonatal mitral valve repair. Very little data on this
patient group is available (2). Valve repair in the neonate is tech-
nically challenging, and replacement with a mechanical prosthe-
sis is associated with significant mortality (11). The aim of this
study is to review the indications for surgery, mechanisms, repair
techniques, and mid-term outcomes of neonatal mitral valve
repair.
MATERIALS AND METHODS
Study Design
This study is a retrospective review of all neonates who underwent
mitral valve repair at our institution between 2005 and 2012. The
demographic, procedural, and outcome data were obtained for all
patients aged <30 days who underwent mitral valve repair dur-
ing the study period. The primary endpoints included mortality,
transplantation, mitral valve reoperation, and moderate regur-
gitation or stenosis at follow-up. Clinical or treatment variables
were recorded to determine predictors of the outcome measures.
All patients underwent follow-up to death or June 2012. The study
was approved by the Boston Children’s Hospital Institutional
Review Board, and individual patient consent was waived.
Surgical Technique
Cardiopulmonary bypass with moderate systemic hypothermia
was used in all patients. Myocardial protection consisted of
antegrade magnesium–lidocaine blood cardioplegia. The surgical
techniques used for mitral valve repair were chosen by the oper-
ating surgeon, based on the mechanisms of mitral valve disease.
The techniques utilized for repair were recorded from review of
operative records.
Statistical Analysis
Statistical analyses were performed with SPSS software (version
21, SPSS Inc., Chicago, IL, USA). Data are presented asmean SD
or median (range) where appropriate. Continuous variables were
analyzed with the Student’s t-test, or the related samples with
Wilcoxon signed-rank test when appropriate, and categorical vari-
ables using the χ2 test or Fisher’s exact test. Actuarial estimates
were calculated using the Kaplan–Meier method, and differences
between curves were assessed by the log-rank test. All statis-
tical tests were two-tailed and P values <0.05 were taken as
significant.
RESULTS
Demographics
Twenty patients were included during the study period. Patient
baseline characteristics are summarized in Table 1. The median
age at operation was 11 days (range: 3–25). Seven patients (35%)
had associated hypoplastic left heart syndrome, six had critical
aortic stenosis (30%), three had Shone’s complex (15%), one had
unbalanced atrioventricular canal, and three had other congenital
heart defects. Eight patients had a fetal intervention, six had
postnatal balloon aortic valvuloplasty, and two had prior opera-
tions to address other congenital heart defects: aortic arch patch
augmentation under low-flow cerebral perfusion and common
atrioventricular canal defect repair in one patient, and coarctation
repair, ventricular septal defect repair, and tricuspid valvuloplasty
in the second patient. Indications for mitral valve repair included
mitral stenosis in 11 patients (55%), regurgitation in 3 (15%), and
mixed mitral disease in 6 patients (30%). Five patients were man-
aged with single ventricle physiology: four patients with HLHS,
and one patient with double outlet right ventricle and hypoplastic
left ventricle and mitral valve; mitral valve repair was considered
in the setting of staged left ventricular recruitment (10).
Mitral Valve Repair
Mitral valve repair consisted of leaflet procedures in 8 patients
(40%), annulus remodeling in 5 patients (25%), and subvalvular
repair in 14 patients (70%). Techniques of valve repair are detailed
in Table 2. Techniques used both in mitral stenosis and regur-
gitation have previously been described in detail (1, 2). In this
subset of patients, most were managed with subvalvular repair
techniques associated with leaflet repairs. Thickened leaflets were
managed by thinning of endocardial fibroelastosis and opening of
fused commissures by commissurotomy. Themobility of retracted
leaflets was improved by thinning fused chords, splitting and
mobilizing papillary muscles, and resection of secondary chords.
Patch augmentation of deficient leaflets was rarely used in this
subset of patients.
TABLE 1 | Baseline patient characteristics.
Characteristic Value
Age at mitral valve repair 11 days (range: 3–25)
Associated congenital cardiac anomalies
Borderline HLHS 7 (35%)
Critical aortic stenosis 6 (30%)
Shone’s complex 3 (15%)
Unbalanced CAVC 1 (5%)
Other 3 (15%)
Type of predominant functional mitral disease
Mitral stenosis 11 (55%)
Mitral regurgitation 3 (15%)
Mixed mitral disease 6 (30%)
Prior interventions
Fetal balloon aortic valvuloplasty 7 (35%)
Fetal balloon mitral valvuloplasty 1 (5%)
Neonatal balloon aortic valvuloplasty 6 (30%)
Neonatal surgical operation 2 (10%)
All data are presented as mean (SD) or number (percentage) unless otherwise noted.
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TABLE 2 | Operative characteristics.
Variable Number (%)
Concomitant procedures
Stage 1 palliation of HLHS 4 (20)
Coarctation repair or arch augmentation 4 (20)
Aortic valvuloplasty 2 (10)
Ross–Konno 4 (20)
ASD repair 3 (15)
ASD restriction or creation 8 (40)
LV endocardial fibroelastosis resection 6 (30)
Subaortic obstruction resection 2 (10)
VSD repair 1 (5)
DORV repair 1 (5)
Aorto-pulmonary window repair 1 (5)
Biventricular repair after failed stage 1 1 (5)
Mitral valve surgical techniques
Leaflet level repair 8 (40)
Commissurotomy 3 (15)
Leaflet tear closure 1 (5)
Cleft closure 1 (5)
Leaflet augmentation 1 (5)
Leaflet thinning 2 (10)
Annulus repair 5 (25)
Reed commissuroplasties 3 (15)
Suture annuloplasty 2 (10)
Subvalvular repair 14 (70)
Papillary muscle mobilization 8 (40)
Fused papillary muscles splitting 6 (30)
Fused chords thinning 1 (5)
Resection of secondary cords 5 (25)
Resection of accessory mitral tissue 1 (5)
Reimplantation of ruptured papillary muscle 1 (5)
Data are presented as median (range) and number (percentage).
ASD, atrial septal defect; HLHS, hypoplastic left heart syndrome; LV, left ventricular.
On postoperative echocardiography, all patients had mild or
trivial mitral regurgitation, with the exception of one patient
with moderate regurgitation and a mean transmitral gradient of
1.4 2.3mmHg. One patient presented a transmitral gradient
7mmHg.
Outcomes
There were no hospital deaths (within 30 days of surgery or prior
to discharge). During a median follow-up of 5months (range:
1month–4.8 years), six patients died at a median of 33months
(range: 1month–3.4 years) from repair and one patient required
orthotopic heart transplantation. The causes of death were low
cardiac output in three patients, diffuse intravascular coagulopa-
thy and liver dysfunction due to a possible storage disease in
one patient, fungal sepsis in one patient, and pulmonary vascular
disease in one patient.
Six patients required mitral valve reoperation, five for mitral
valve re-repair, and one formitral valve replacement. Two patients
underwent mitral valve re-repair at bidirectional Glenn in the
setting of secondary LV recruitment, and one patient under-
went mitral valve re-repair for moderate stenosis (mean gradient
7.5mmHg) during reoperation for recurrent left ventricular out-
flow tract and aortic valve obstruction, after fetal and neonatal
aortic balloon valvuloplasty and neonatal surgical aortic valvulo-
plasty. Two patients underwent isolated mitral valve reoperation,
one for recurrent mitral regurgitation due to a perforation in the
anterior mitral leaflet at the site of insertion of an autologous
pericardial patch augmenting the leaflet and one for recurrent
mixed mitral disease after repair for congenital mitral and aortic
stenosis. This patient’s first repair had included resection of sec-
ondary chords, leaflet thinning, and commissuroplasty. At reop-
eration, the anterior leaflet and posterior leaflets were thinned,
secondary chords were divided, and fused papillary muscles were
divided and mobilized from the ventricular wall. The patient
who required mitral valve replacement originally had a repair for
ischemic mitral regurgitation due to papillary muscle rupture. As
the papillary muscle re-ruptured within 3months with recurrent
severe mitral regurgitation, the valve was replaced using a mod-
ified stented bovine internal jugular vein (Melody) valve in the
mitral position (12, 13). This patient, who previously had severe
left ventricular dysfunction which did not improve after mitral
valve replacement, was listed for transplantation and subsequently
underwent orthotopic heart transplantation.
Freedom from death, transplantation, or mitral valve replace-
ment was 84.2 8.4% at 1month, 71.3 11% at 6months,
64.1 12% at 1 year, and 51.3 15% at 2 years (see Figure 1).
Freedom from this composite endpoint was 81.8 11.6% at
1month, 6months, 1 year, and throughout follow-up in the 11
patients with mitral stenosis, 83.3 15.2% at 1 and 6months,
62.5 21.3% at 1 year, and 0% at 2 years in the 6 patients with
mixed mitral disease, and 50 35.4% at 1month and 0% at
6months in the 3 patients withmitral regurgitation (P= 0.003, see
Figure 2). When placing mixed lesions either in the group with
stenosis or regurgitation based on the predominant mechanism,
this difference between curves became non-significant (P= 0.72).
Figure 3 provides the Kaplan–Meier estimates of freedom from
mitral valve reoperation.
At the latest follow-up of transplant-free survivors (n= 13),
seven patients demonstrate none to trivial mitral regurgitation,
six patients demonstrate mild mitral regurgitation, and none have
moderate or severe regurgitation. The mean transmitral gradi-
ent was 4.3 2.7mmHg (one patient with gradient >7mmHg).
With regards to pulmonary hypertension, one patient presented
systemic pulmonary pressure after primary neonatal left ventric-
ular rehabilitation for borderline HLHS (MS/AS), after neona-
tal mitral valve repair, subaortic stenosis resection, LV EFE
resection, and aortic arch augmentation. This patient presented
mild mitral regurgitation and no mitral stenosis on the latest
echocardiogram. All other patients had no significant pulmonary
hypertension.
Table 3 summarizes predictors of death, transplantation, or
mitral valve replacement. Although there were minor differences
in baseline and operative variables between patients who met
the study endpoint versus those who did not, these differences
were not statistically significant. Among patients who underwent
stage 1 palliation of borderline HLHS, three did not reach the
composite endpoint, while one died. Excluding these patients
managed with single ventricle palliation, the median LV end-
diastolic volume (LVEDV) and long axis Z-scores did not differ
significantly between groups (LVEDV  1.69, range:  3.1 to 6.47
among patients notmeeting the endpoint, versus 0.1, range: 1.81
to 2.14 among those reaching the endpoint, P= 0.37; LV long axis
Z-score  1.16, range:  2.9 to 2.7 versus  0.42, range:  1.90 to
 0.07, P= 0.84).
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FIGURE 1 | Kaplan–Meier estimate of freedom from death, transplantation, or mitral valve replacement.
DISCUSSION
This retrospective review highlights a single institution experi-
ence with neonatal mitral valve repair. Subvalvular pathology
is a predominant component of the mitral disease. Although
postoperative outcomes are acceptable, reintervention is common.
Children are increasingly being referred for valve repair, which
likely results from the improving survival for complex congenital
heart disease (5) and the focus on the development of valve repair
and complex reconstruction rather than replacement (1). Valve
repair in neonates is usually deferred as long as the patient can be
managedmedically, as repair is technically challenging, due to the
greater fragility of the leaflet tissue, the often complex mechanism
of mitral valve dysfunction in neonates, the significant mortality
associated with valve replacement in small children (11), and the
option to delay repair or choose single ventricle palliation, with
proven results and outcomes (14).
There is an increased interest in neonatal mitral valve repair,
with improving results in the management of congenital mitral
valve disease in children (1, 2, 4–6), as well as the shortcomings of
single ventricle palliation at long-term follow-up, and an increased
interest in biventricular repair in borderline hypoplastic hearts
(9, 10). Furthermore, delaying valve repair in selected patient
groups is associated with worse outcomes: delaying valve repair in
neonates with truncus arteriosus and truncal valve regurgitation
is associated with an increased risk of mortality (15–17), while
neonatal repair of this valve is associated with outcomes superior
to infants or children undergoing truncal valve repair (15). Aortic
valve repair in newborns has also been shown to have excellent
results, which are superior to balloon valvuloplasty in neonatal
aortic stenosis (18–20). These examples illustrate that aortic valve
repair in the neonatal period is feasible and improves outcomes in
selected difficult patient groups. The same needs to be assessed in
other settings, such as congenital mitral disease.
As techniques for mitral valve in children have developed, so
has the ability to apply these techniques to neonates aswell as older
children. Improvements in echocardiographic imaging allow the
surgeon to assess the contribution of the various components of
the mitral apparatus to overall valvular dysfunction. The high rate
of immediate postoperative technical success demonstrated in this
study is reflective of the improvements in imaging and techniques.
However, in contrast to children and adult, the durability of the
repair is suboptimal as demonstrated in this study. The reason for
the poor durability is unclear, but may be related to accelerated
degeneration of repair and high sensitivity to minor alterations in
annular, leaflet, or papillary geometry.
Avoiding intervention in the neonatal period and deferring sur-
gical management of themitral valve until infancymay reduce the
rate of reintervention, but raises the risk of progressive pulmonary
vascular disease and interim mortality. In a study of 63 neonates
with aortic coarctation and associated hypoplasia of either the
aortic or mitral valve, who underwent biventricular neonatal
repair with isolated coarctation repair, the mean mitral valve
Z-score increased from 3.5 1.9 at birth to+0.7 1.6 at follow-
up without intervention on the mitral valve (21). The strategy
of single ventricle management may avoid the consequences of
relying upon a diseasedmitral valve for systemic output, but incurs
the long-term risks of single ventricle physiology. An alternative
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FIGURE 2 | Kaplan–Meier estimate of freedom from death, transplantation, or mitral valve replacement stratified by the mechanism of mitral valve
dysfunction. MR, mitral regurgitation; MS, mitral stenosis; MS/MR, mixed mitral disease.
FIGURE 3 | Kaplan–Meier estimate of freedom from mitral valve reoperation.
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TABLE 3 | Predictors of death, transplantation, or mitral valve replacement.
Risk factor Endpoint-
free
Endpoint P value
Associated anomalies 0.17
HLHS 6 (46%) 1 (14%)
Shone’s complex 3 (23%) 0 (0%)
Unbalanced CAVC 0 (0%) 1 (14%)
Critical aortic stenosis 3 (23%) 3 (43%)
Other congenital cardiac anomaly 1 (8%) 2 (29%)
Type of predominant functional mitral valve
dysfunction
0.23
Stenosis 9 (69%) 2 (29%)
Regurgitation 1 (8%) 2 (29%)
Mixed mitral disease 3 (23%) 3 (43%)
Prior interventions
Fetal balloon aortic valvuloplasty 6 (46%) 1 (14%) 0.33
Fetal balloon mitral valvuloplasty 1 (8%) 0 (0%) >0.99
Neonatal balloon aortic valvuloplasty 4 (31%) 2 (29%) >0.99
Neonatal surgical operation 0 (0%) 2 (29%) 0.11
Left ventricular dimensions
LVEDV Z-score  2.1
( 4.71 to
6.47)
 1.36
( 4.25 to
2.14)
0.75
LV long axis dimension Z-score  1.16
( 5.4 to
2.73)
 0.89
( 3.38 to
 0.07)
0.82
Mitral valve repair surgical techniques
Leaflet repair 6 (46%) 2 (29%) 0.64
Annulus remodeling 3 (23%) 2 (29%) >0.99
Subvalvular repair 9 (69%) 2 (71%) >0.99
Concomitant procedure
Stage 1 palliation of HLHS 3 (23%) 1 (14%) >0.99
Coarctation repair or arch augmentation 4 (31%) 0 (0%) 0.25
Aortic valvuloplasty 2 (15%) 0 (0%) 0.52
Ross–Konno 3 (23%) 1 (14%) >0.99
ASD restriction 5 (39%) 2 (29%) >0.99
LV EFE resection 5 (39%) 1 (14%) 0.35
ASD, atrial septal defect; EFE, endocardial fibroelastosis; HLHS, hypoplastic left heart
syndrome; LV, left ventricular.
strategy of single ventricle palliation to support the circulation
while maneuvers are performed to repair the mitral valve allows
conversion to biventricular circulation once the mitral disease has
been stabilized (10). This strategy was applied for one patient in
this series with anticipated biventricular conversion. Expanded
use of this strategy may reduce the risk of pulmonary vascular
disease and short-term mortality in patients with severe forms of
mitral pathology. Improvements in mitral valve prostheses allow
replacement to be a viable strategy for neonates (12, 13).
There is a paucity of data on neonatal mitral valve repair. Our
group previously reported our experience in managing congenital
mitral stenosis, with significantlyworse freedom from reoperation
in neonates than in infants and children (2). One report on neona-
tal mitral valve repair (22) described repair of in utero papillary
muscle rupture in two neonates with tricuspid regurgitation and
one 7-week-old infant with mitral regurgitation. Although there
are numerous reports of mitral valve repair in children (1–4, 6,
23, 24), none of these have focused on or analyzed the subset of
patients who required mitral valve repair in the neonatal period.
The present study reports the surgical repair of mitral valve
disease in 20 neonates. These patients presented a mix of
complex congenital heart disease, including Shone’s complex,
borderline hypoplastic left heart syndrome, unbalanced common
atrioventricular canal, critical aortic stenosis, or double outlet
right ventricle, and five of these patients underwent single ven-
tricle palliation. Mitral valve repair is composed of a mix of tech-
niques, from simple commissurotomy to leaflet thinning, patch
augmentation, and extensive subvalvular repair. Although there
was a high burden of reoperation, using complex repairs, includ-
ing on the leaflets or subvalvar apparatus, did not increase the
rate of repair failure. Although a large proportion of our patients
had congenital mitral stenosis, only one patient had patch aug-
mentation with autologous pericardium.We previously described
our institutional approach to this disease, which often involves
incising the posterior leaflet from the annulus to gain access to
the subvalvar apparatus, allowing mobilization of fused cords and
papillary muscles (2). Patch augmentation of the posterior leaflet
improves mobility, although mid- and long-term results of patch
augmentation of the mitral valve is overall poor (25), due to
limitations of currently available patch materials (26).
In this study, neonates with mitral regurgitation had worse
outcomes compared to patients with mixed mitral disease or
mitral stenosis. The data in older children would tend to show the
inverse relationship (1). Our analysis may be confounded by the
small sample size, and particularly the fact that just three patients
had isolated mitral regurgitation. These patients tended to be
sicker: two patients had severe biventricular dysfunction before
mitral valve repair, and one patient required orthotopic heart
transplantation and the other died secondary to liver dysfunction,
with a suspected storage disease. The third patient had a relatively
more simple disease (aorto-pulmonary window, mitral regurgi-
tation due to a dilated mitral annulus and normal ventricular
function), which was managed with suture annuloplasty at the
time of aorto-pulmonary window repair, with a good outcome.
The underlying severity of disease could be considered the reason
for worse outcomes in this small group of patients with neonatal
mitral regurgitation.
This study has several limitations. First, this was a retrospective,
non-interventional study designed to evaluate the outcomes of an
established clinical program. All patients were managed as indi-
viduals and not according to a treatment protocol, which would
have improved our ability to analyze outcomes. Our analyses were
limited by the limited patient sample, even if this represents one
of the largest populations of neonatal mitral valve repair. Further-
more, the surgical techniques used included various techniques of
mitral valve repair, as well asmany differing underlying anatomies
and associated anomalies or physiology, including single ventricle
palliation, which may confound the analysis.
CONCLUSION
Mitral valve repair can be done in neonates who require it, with
low operative risk and allows valve preservation in a majority of
patients at mid-term follow-up. This patient group carries a high
burden of late death and mitral valve reoperations.
AUTHOR NOTE
Presented at the STS 50th annual meeting in Orlando, FL on
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